As governments around the world seek to tackle urgent health care and environmental challenges by increasing public funding for research and development, some critics of the intellectual property system claim that the results of this research belong exclusively in the public domain. These critics take issue with the current U.S. system that allows universities and companies applying or using federally funded research as a basis for further innovation or for commercializing a product to retain the patent rights with respect to that product.